🇺🇸 FDA
Patent

US 8865723

Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury

granted A61KA61K31/505A61K31/506

Quick answer

US patent 8865723 (Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury) held by Tetra Discovery Partners expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tetra Discovery Partners
Grant date
Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/505, A61K31/506